RxDoctor Payments Data

Georges Ramalanjaona, MD

General Practice · Bronx, NYNPI 1104811785

Payments from drug & device makers

$430in general payments, 2019–2025

Across 9 payments — averaging $47.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$179
  • Avanir Pharmaceuticals, Inc.$159
  • Acadia Pharmaceuticals Inc$68
  • Boston Scientific$24

What the payments were for

  • Food & beverage$430100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$430 in reported general payments places this provider in the 60th percentile of 5,764 general practice providers in New York.

See all general practice providers in New York

Medicare billing

Part B allowed, 2024
$730,005
Medicare patients
958
Services billed
5,962

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala142$592,849
EliquisApixaban1,084$331,257
TivicayDolutegravir Sodium130$151,864
Humira(Cf)Adalimumab19$140,138
JardianceEmpagliflozin299$99,835
EntrestoSacubitril/Valsartan290$99,758
TriumeqAbacavir/Dolutegravir/Lamivudi25$99,660
Humira(Cf) PenAdalimumab13$95,449
JanuviaSitagliptin Phosphate290$87,041
XareltoRivaroxaban309$86,948
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf11$55,036
PrezcobixDarunavir/Cobicistat41$50,316
XifaxanRifaximin24$46,191
SantylCollagenase Clostridium Hist.82$41,972
Teriparatide13$36,780

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$179$62,701157 claims
Avanir Pharmaceuticals, Inc.Nuedexta$159$35,83745 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 5,764 general practice providers in New York.

Other general practice in Bronx

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →